Multimarker Serum Testing Related to Ovarian Cancer
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governs coverage and prior authorization for FDA-cleared multimarker serum tests (OVA1, Overa, ROMA) used to assess malignancy risk in women with ovarian adnexal masses for Blue Cross Blue Shield - Rhode Island members.
Effective 9/1/2026, OVA1 (CPT 81503) is considered medically necessary when online authorization criteria are met for Medicare Advantage and Commercial Products.
Overa (0003U) and ROMA (81500) are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products for all uses.
Prior authorization is recommended for Commercial Products via the online tool for OVA1.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.